Ranbaxy Laboratories, a division of Daiichi Sankyo Company, and EPIRUS Switzerland GmbH, a wholly-owned subsidiary of Boston-based EPIRUS Biopharmaceuticals, Inc., have inked a licensing agreement for BOW015, a biosimilar version of Infliximab.https://www.epicresearch.co/
No comments:
Post a Comment